A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Clinical trial NCT02411448 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02411448
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-06
- Primary completion
- 2019-01-23
- Enrollment
- 545
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.